Transcatheter Aortic Valve Replacement (TAVR) Market Poised to Reach USD 12.91 Billion by 2034, Growing at a CAGR of 6.7%
The global transcatheter aortic valve replacement (TAVR) market was valued at USD 6.78 billion in 2024 and is expected to expand at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2034. Market growth is primarily driven by the rising prevalence of cardiac valve disorders and the increasing proportion of the elderly population worldwide.
Key Drivers & Technological Trends
- Rising preference for minimally invasive procedures
TAVR is increasingly preferred over surgical aortic valve replacement (SAVR), offering lower risk, shorter hospital stays, and faster recovery - Advances in valve technologies
- Self-expanding valves held ~66% market share in 2024, due to improved hemodynamics, especially in women
- Balloon-expandable valves remained dominant (~55–56%) owing to precision deployment and long-term data .
- Recent clinical evidence shows comparable or superior performance of self-expandable valves in specific patient segments
TAVR is expanding beyond high-risk cases into intermediate and low-risk groups, supported by growing clinical trial data Transfemoral access remains dominant (>50% of procedures), with adoption of transapical and transaortic routes
In 2024, hospitals accounted for ~88% of procedures, but ambulatory surgical centers (ASCs) are gaining traction for cost efficiency and convenience
Strategic acquisitions (e.g., Edwards acquiring JC Medical in 2024) and CE-mark approvals (e.g., Boston Scientific’s ACURATE Prime) are accelerating product development
Market Size & Forecast
- Market Size in 2024 – USD 6.78 billion
- Projected Market Size by 2034 – USD 12.91 billion
- CAGR (2025–2034) – 6.7%
Request a free sample copy or view report summary: https://www.polarismarketresearch.com/industry-analysis/transcatheter-aortic-valve-replacement-tavr-market/request-for-sample
Market Overview
The Transcatheter Aortic Valve Replacement (TAVR) market is witnessing robust growth globally, driven by the increasing prevalence of aortic stenosis, rising geriatric population, and advancements in minimally invasive cardiac procedures. TAVR has emerged as a preferred alternative to traditional open-heart surgery for patients with severe aortic valve stenosis, especially among elderly and high-risk individuals
The Transcatheter Aortic Valve Replacement (TAVR) market has emerged as a transformative segment of interventional cardiology, offering a minimally invasive treatment alternative to traditional surgical aortic valve replacement (SAVR). Designed primarily for patients suffering from severe aortic stenosis who are deemed inoperable or at high surgical risk, the TAVR procedure is now witnessing widespread adoption across intermediate- and even low-risk patient populations. The expansion of indications, technological advancements, and global demographic shifts—particularly aging populations—are fueling robust growth in this market.
